A detailed history of Everence Capital Management Inc transactions in Alkermes Plc. stock. As of the latest transaction made, Everence Capital Management Inc holds 9,540 shares of ALKS stock, worth $281,143. This represents 0.02% of its overall portfolio holdings.

Number of Shares
9,540
Previous 18,380 48.1%
Holding current value
$281,143
Previous $514,000 46.69%
% of portfolio
0.02%
Previous 0.03%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 03, 2025

SELL
$25.7 - $31.46 $227,188 - $278,106
-8,840 Reduced 48.1%
9,540 $274,000
Q3 2024

Oct 21, 2024

BUY
$23.01 - $28.55 $117,581 - $145,890
5,110 Added 38.51%
18,380 $514,000
Q1 2024

May 08, 2024

BUY
$26.4 - $32.56 $117,216 - $144,566
4,440 Added 50.28%
13,270 $359,000
Q4 2023

Jan 30, 2024

BUY
$23.37 - $28.68 $206,357 - $253,244
8,830 New
8,830 $245,000

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.84B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Everence Capital Management Inc Portfolio

Follow Everence Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Everence Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Everence Capital Management Inc with notifications on news.